TGN1412
TGN1412
TGN1412 (/ˈtiːdʒiːɛnˈfɔːrtiːnwʌnˈtuː/) is a monoclonal antibody that was developed for the treatment of autoimmune diseases and leukemia.
Etymology
The name "TGN1412" is derived from the initials of the company that first developed it, TeGenero (TGN), and the number 1412 is an arbitrary designation.
History
TGN1412 was first developed by the German biotechnology company TeGenero. In 2006, it was the subject of a clinical trial in London that resulted in severe systemic organ failure in six volunteers. This incident, often referred to as the "Northwick Park Incident", led to significant changes in the guidelines for first-in-human clinical trials.
Mechanism of Action
TGN1412 is a superagonist of the CD28 receptor on T cells. It is designed to activate T cells in the absence of a co-stimulatory signal, which is normally required for T cell activation. This unique mechanism of action was intended to make TGN1412 a powerful tool for modulating the immune response in diseases where the immune system is overactive, such as autoimmune diseases and leukemia.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune diseases: Conditions in which your immune system mistakenly attacks your body.
- Leukemia: A type of cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system.
- CD28: A co-stimulatory protein that is important in the immune response and T cell activation.
- T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity.
External links
- Medical encyclopedia article on TGN1412
- Wikipedia's article - TGN1412
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski